Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2007-11-28
2009-10-06
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007100, C435S007230, C436S513000, C436S064000
Reexamination Certificate
active
07598028
ABSTRACT:
The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and/or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).
REFERENCES:
Adamson Ed et al., “Egr1 transcription factor: muitiple roles in prostate tumor cell growth and survival.” Tumour Biol. 2002 vol. 23:93-102.
Ao M et al., “Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.” Cancer Res. 2007 67(9) pp. 4244-53.
Arenas MI et al., “Morphometric evaluation of the human prostate.” Int. J. Andrology 2001 vol. 24 pp. 37-47.
Begley L, “Concordant copy No. and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro.” Genes Chromosomes Cancer. 2006 45(2) pp. 136-146.
Begley L. et al., “CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro.” Aging Cell 2005 vol. 4(6):291-8.
Begley LA et al., “CXCL12 activates a robust transcriptional response in human prostate epithelial cells.” J Biol Chem 2007 vol. 282(37):26767-74.
Berger AP et al., “Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL.” Urology 2003 vol. 62 pp. 840-4.
Berger AP et al.: “Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.” Urology 2007 vol. 69 pp. 134-138.
Berges RR et al., “Implication of cell kinetic changes during the progression of human prostatic cancer.” Clin. Cancer Res. 1995 vol. 1 pp. 473-480.
Burns JM et al., “A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.” J. Exp. Med. 2006 203(9):2201-13.
Cunha GR et al., “Smooth muscle-epithelial interactions in normal and neoplastic prostatic development” Acta Anat. 1996 vol. 155 pp. 63-72.
Darash-Yahana M. et al., “Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.” FASEB J. 2004 vol. 18(11).
Gilbert SM et al., “Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies” Urology 2005 vol. 65 pp. 549-553.
Hayward SW et al., “Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model”. Differentiation 1998 vol. 63 pp. 131-140.
Inahara M. et al., “Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.” Urology 2006 vol. 68 pp. 815-819.
Kravchick S. et al., “Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL,” Urology 2005 vol. 66 pp. 542-546.
Kukreja P. et al., “Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation.” Cancer Res 2005 65(21) pp. 9891-9898.
Luciani LG et al., “Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings” Urology 2006 vol. 67 pp. 555-558.
Macoska JA et al., Cancer Genet. Cytogenet. 2005 vol. 154 pp. 36-43.
Meigs JB et al, “Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men” J. Clin. Epidemiol. vol. 54 pp. 935-944 (2001).
Mochizuki H. at al., “Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis” Biochem Biophys Res Commun. 2004 vol. 320(3):656-63.
Neuhouser ML et al., “Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature” Urology 2004 vol. 64 pp. 201-211.
Olumi AF et al., “A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death” Cancer Res. 1998 vol. 58 pp. 4525-4530.
Pelzer AE et al , “Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project”Urology 2005 vol. 66 pp: 1029-1033.
Pinsky PF et al., “Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial” Urology 2006 vol. 68 pp. 352-6v.
Wright EJ et al., J. Urol. 2002 vol. 167 pp. 2484-2487.
Simardi L.H et al., “Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study” Urology 2004 vol. 64 pp. 1098-1101.
Singh S. et al., “CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion” Lab Invest. 2004 vol. 84(12):1666-76.
Taichman RS et al., “Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone” Cancer Res. 2002 62(6).
Thompson TC et al., “Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ” Cell 1989 vol. 56 pp. 917-930.
Wang J. et al., “Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis” Cellular Signaling 17 2005 pp. 1578-1592.
Casimir Jones SC
Helms Larry R.
The Regents of the University of Michigan
Yao Lei
LandOfFree
Compositions and methods for detecting and treating prostate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for detecting and treating prostate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for detecting and treating prostate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081515